^
    Back
    Association details:
    Biomarker:RANBP2-ALK fusion
    Cancer:Chronic Myelomonocytic Leukemia
    Drug:cytarabine (DNA synthesis inhibitor, DNA-directed DNAP inhibitor) +
    daunorubicin (Topoisomerase II inhibitor, DNA intercalator)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C4 – Case Studies
    Source:
    Springer
    Title:

    inv(2)(p23q13)/RAN-binding protein 2 (RANBP2)–ALK fusion gene in myeloid leukemia that developed in an elderly woman

    Published date:
    12/04/2013
    Excerpt:
    A 75-year-old woman presented with marked leukocytosis...RAN-binding protein 2 (RANBP2)–ALK fusion mRNA was confirmed by reverse transcriptase-mediated polymerase chain reaction and nucleotide sequencing...As the leukemia showed features of chronic myelomonocytic leukemia, the patient was treated with standard daunorubicin-cytarabine followed by azacitidine, leading to the durable suppression of leukemia progression.
    Secondary therapy:
    azacitidine
    DOI:
    10.1007/s12185-013-1482-x